Volitionrx Ltd (VNRX)

Apr 1, 2025, 12:31 AM EDT - 23 days ago

VolitionRx Limited (VNRX) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 4:05 PM EDT - 23 days ago

VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update

Mar 28, 2025, 8:00 AM EDT - 27 days ago

Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025

Mar 27, 2025, 8:30 AM EDT - 4 weeks ago

Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025

Mar 26, 2025, 8:00 AM EDT - 4 weeks ago

VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering

Mar 25, 2025, 9:30 AM EDT - 4 weeks ago

VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update

Mar 21, 2025, 8:30 AM EDT - 4 weeks ago

Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry

Mar 20, 2025, 8:30 AM EDT - 5 weeks ago

Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer

Mar 17, 2025, 8:30 AM EDT - 5 weeks ago

Volition Proudly Sponsors the 44th ISICEM Congress

Mar 13, 2025, 8:30 AM EDT - 6 weeks ago

Volition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet Systems

Mar 11, 2025, 8:30 AM EDT - 6 weeks ago

Volition Announces First Patient Enrolled in NTU Hospital's Prospective Validation Study of Nu.Q® Lung Cancer Test

Mar 4, 2025, 8:30 AM EST - 7 weeks ago

Volition's Nu.Q® Discover Biomarkers to be utilized in Human Clinical Study Sponsored by Leading Pharmaceutical Company for the First Time

Feb 28, 2025, 8:30 AM EST - 7 weeks ago

Volition Showcases Nu.Q® Vet Cancer Test at the 97th WVC Annual Conference

Feb 6, 2025, 8:30 AM EST - 2 months ago

Volition Signs First Commercial Project Utilizing Rapid High-Throughput Model in the Study of NETosis

Feb 5, 2025, 9:15 AM EST - 2 months ago

Volition to Host Virtual Investor Event on Nu.Q® NETs, "Casting a New Light on Sepsis Management", on February 14, 2025

Jan 30, 2025, 8:30 AM EST - 3 months ago

Large clinical study establishes Nu.Q® NETs H3.1 as an independent predictor of 28-day mortality in sepsis

Jan 8, 2025, 8:30 AM EST - 3 months ago

Volition Issues Business Review 2024

Dec 12, 2024, 8:00 AM EST - 4 months ago

VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants

Dec 10, 2024, 8:00 AM EST - 4 months ago

Study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening

Dec 6, 2024, 9:00 AM EST - 4 months ago

VolitionRx Announces Pricing of up to $1.9 Million Registered Direct Offering

Nov 15, 2024, 11:47 AM EST - 5 months ago

VolitionRx Limited (VNRX) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 4:10 PM EST - 5 months ago

VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update

Nov 8, 2024, 8:00 AM EST - 5 months ago

VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update

Nov 6, 2024, 4:10 PM EST - 6 months ago

Volition Appoints Timothy I. Still as Chairman

Oct 31, 2024, 8:00 AM EDT - 6 months ago

Multiple studies show Nu.Q® NETs test could predict sepsis patients at risk of deteriorating

Oct 9, 2024, 8:00 AM EDT - 7 months ago

Volition to share new 'NETs in sepsis management' data insights at upcoming webinar

Oct 3, 2024, 8:00 AM EDT - 7 months ago

Volition hosts NETs in sepsis management symposium at ESICM Lives 2024

Sep 30, 2024, 4:10 PM EDT - 7 months ago

Volition Appoints Dr. Ethel Rubin as an Independent Director

Sep 11, 2024, 8:00 AM EDT - 8 months ago

Volition Hosts KOL Roundtable on Sepsis

Aug 15, 2024, 12:11 PM EDT - 8 months ago

VolitionRx Limited (VNRX) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 4:10 PM EDT - 9 months ago

VolitionRx Limited Announces Second Quarter 2024 Financial Results and Business Update

Aug 9, 2024, 8:00 AM EDT - 9 months ago

VolitionRx Announces Pricing of up to $21.5 Million Registered Direct Offering

Aug 6, 2024, 8:00 AM EDT - 9 months ago

VolitionRx Limited Schedules Second Quarter 2024 Earnings Conference Call and Business Update

Jul 9, 2024, 8:30 AM EDT - 10 months ago

Volition appoints PharmaVentures for Capture PCR™ and oncology portfolio licensing

Jun 27, 2024, 8:00 AM EDT - 10 months ago

VolitionRx Limited Issues Mid-Year Review Ahead of 2024 Annual Meeting

Jun 14, 2024, 9:00 AM EDT - 11 months ago

Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

NXL

May 29, 2024, 8:00 AM EDT - 11 months ago

VolitionRx Limited to Present at Jefferies Global Healthcare Conference

May 14, 2024, 8:24 PM EDT - 1 year ago

VolitionRx Limited (VNRX) Q1 2024 Earnings Call Transcript

May 13, 2024, 4:10 PM EDT - 1 year ago

VolitionRx Limited Announces First Quarter 2024 Financial Results and Business Update

May 8, 2024, 8:00 AM EDT - 1 year ago

VolitionRx Limited Schedules First Quarter 2024 Earnings Conference Call and Business Update

Apr 23, 2024, 8:00 AM EDT - 1 year ago

Nu.Q® Vet Cancer Test launched in-clinic in U.S. and Europe through Antech

Mar 26, 2024, 12:43 PM EDT - 1 year ago

VolitionRx Limited (VNRX) Q4 2023 Earnings Call Transcript

Mar 25, 2024, 4:10 PM EDT - 1 year ago

VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update

Mar 21, 2024, 8:30 AM EDT - 1 year ago

VolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business Update

Mar 20, 2024, 8:30 AM EDT - 1 year ago

Volition and Fujifilm Vet Systems Launch Nu.Q® Vet Cancer Test in Japan

Mar 19, 2024, 4:30 PM EDT - 1 year ago

Volition appoints Dr Andrew Retter as Chief Medical Officer

Feb 2, 2024, 8:00 AM EST - 1 year ago

Volition to Share Nu.Q® NETs Strategy Update at Upcoming Webinar

Jan 4, 2024, 8:00 AM EST - 1 year ago

Volition Issues Business Review 2023

Dec 5, 2023, 8:00 AM EST - 1 year ago

VolitionRx Secures Approximately $5.5 Million in Belgium Regional Government Financing from Wallonie Entreprendre

Nov 15, 2023, 3:41 PM EST - 1 year ago

VolitionRx Limited (VNRX) Q3 2023 Earnings Call Transcript